No connection

Search Results

ABUS vs QDEL

ABUS
Arbutus Biopharma Corporation
BEARISH
Price
$4.53
Market Cap
$872.0M
Sector
Healthcare
AI Confidence
85%
QDEL
QuidelOrtho Corporation
BEARISH
Price
$12.71
Market Cap
$865.3M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABUS
--
QDEL
--
Forward P/E
ABUS
-27.41
QDEL
4.39
P/B Ratio
ABUS
11.38
QDEL
0.45
P/S Ratio
ABUS
61.92
QDEL
0.32
EV/EBITDA
ABUS
-29.91
QDEL
6.32

Profitability

Gross Margin
ABUS
-79.23%
QDEL
46.81%
Operating Margin
ABUS
-727.31%
QDEL
4.01%
Profit Margin
ABUS
-237.88%
QDEL
-41.45%
ROE
ABUS
-38.52%
QDEL
-46.15%
ROA
ABUS
-14.94%
QDEL
1.27%

Growth

Revenue Growth
ABUS
-33.2%
QDEL
2.2%
Earnings Growth
ABUS
--
QDEL
--

Financial Health

Debt/Equity
ABUS
0.05
QDEL
1.49
Current Ratio
ABUS
15.73
QDEL
1.5
Quick Ratio
ABUS
15.52
QDEL
0.77

Dividends

Dividend Yield
ABUS
--
QDEL
--
Payout Ratio
ABUS
0.0%
QDEL
0.0%

AI Verdict

ABUS BEARISH

ABUS exhibits severe financial distress signals with a Piotroski F-Score of 0/9, indicating extreme weakness in operational and financial health. The company reports massive negative margins, declining revenue, and unprofitable operations, with no meaningful cash flow or profitability. While the low debt-to-equity ratio and high current ratios suggest strong liquidity, they are likely inflated by non-operational cash reserves. The absence of a Graham Number and intrinsic value estimate reflects a lack of sustainable earnings, and the stock trades at a premium valuation despite deteriorating fundamentals. Analysts offer no consensus, and insider activity is neutral, reinforcing a lack of confidence.

Strengths
High current and quick ratios (15.73 and 15.52) indicate strong short-term liquidity
Low debt-to-equity ratio (0.05) suggests minimal leverage risk
Recent 1-year return of +34.4% shows strong price momentum despite fundamentals
Risks
Piotroski F-Score of 0/9 signals severe financial distress and operational failure
Negative profit margins (up to -237.88%) and declining revenue (-33.20% YoY) indicate deteriorating business model
No operating cash flow or free cash flow data available, raising concerns about sustainability
QDEL BEARISH

QuidelOrtho exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a technical trend score of 0/100. Despite appearing 'cheap' on a Price-to-Book (0.45) and Price-to-Sales (0.32) basis, the company suffers from negative profit margins (-41.45%) and a catastrophic 5-year price decline of 89.6%. The disconnect between the bullish analyst target ($30.83) and the deteriorating fundamental health suggests a classic value trap. The lack of revenue growth (2.2%) and negative ROE (-46.15%) further undermine any recovery thesis.

Strengths
Deeply undervalued Price-to-Book ratio (0.45)
Low Price-to-Sales ratio (0.32)
Strong Gross Margin (46.81%)
Risks
Critically low Piotroski F-Score (2/9) indicating fundamental weakness
Severe negative profit margins (-41.45%)
Extreme bearish price momentum (1Y change -49.5%, 6M change -54.8%)

Compare Another Pair

ABUS vs QDEL: Head-to-Head Comparison

This page compares Arbutus Biopharma Corporation (ABUS) and QuidelOrtho Corporation (QDEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile